Litigation Details for Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2017)
| Docket | ⤷ Subscribe | Date Filed | 2017-12-15 |
| Court | District Court, D. Delaware | Date Terminated | 2018-02-12 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Parties | WATSON LABORATORIES, INC. | ||
| Patents | 7,829,595; 9,375,405 | ||
| Attorneys | Maryellen Noreika | ||
| Firms | JPMorgan Chase & Co. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Amgen Inc. v. Watson Laboratories, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Details for Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-12-14 | 1 | inter alia, the ’405 patent and its parent, U.S. Patent No. 7,829,595 (“the ’595 patent”). … infringement of U.S. Patent No. 9,375,405 (the “’405 patent”) under the Patent Laws of the United States… THE PATENT-IN-SUIT 11. On June 28, 2016, the ’405 patent, titled “Rapid …United States Patent and Trademark Office (“PTO”). 12. The ’405 patent is assigned to…reviews pharmaceutical patents and seek opportunities to challenge those patents. 24. | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
